trilaciclib
trilaciclib is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including COSELA. Available dosage form: injection, powder, lyophilized, for solution.
Drug Details
- Generic Name
- trilaciclib
- Brand Names
- COSELA
- Application Number
- NDA214200
- Sponsor
- Pharmacosmos Therapeutics Inc.
- NDC Codes
- 2
- Dosage Forms
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Routes
- INTRAVENOUS
- Active Ingredients
- TRILACICLIB DIHYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). COSELA is a kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. ( 1 )